SPY 002
Alternative Names: PR-010; SPY-002; SPY-002-091; SPY002 072Latest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator Paragon Therapeutics
- Developer Spyre Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 02 Dec 2024 Spyre Therapeutics plans a phase II trial for an unspecified indication in 2025
- 02 Dec 2024 Spyre Therapeutics plans a phase II trial for Ulcerative colitis (Monotherapy, Combination therapy) in 2025
- 18 Nov 2024 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in Canada (SC) (NCT06622070)